Gastrointestinal

Redx Pharma previews development plans for idiopathic pulmonary fibrosis and fibrostenotic Crohn’s disease

CMO Dr Jane Robertson shares a sneak peek into trial designs for assets in IPF and Crohn’s disease planned for 2023/2024.